Examination of relationship between quality of life and adverse events in the first -line treatment including cetuximab for KRAS wild-type unresectable colorectal cancer
Latest Information Update: 12 Jul 2022
At a glance
- Drugs Cetuximab (Primary) ; Antineoplastics
- Indications Colorectal cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms QUACK
- 28 Jun 2022 Results of an analysis of HRQOL using the EORTC QLQ-C30 published in the BMC Cancer
- 04 Jul 2020 Results presented at the 22nd World Congress on Gastrointestinal Cancer.
- 26 Jul 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.